FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 73 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Dr Ian Walker on Smoking: ‘A political no-brainer’ March 24, 2023 Heartburn Medications Pulled From Shelves Because They May Cause Cancer January 13, 2020 Maintenance Therapy with CC-486 Extends Survival of Adults with AML January 16, 2020 A cut above: Making drug discovery more efficient using CRISPR August 16, 2022 Load more HOT NEWS New Safety Signal for Use of Ibrutinib in Combination with Rituximab... Suzanne Somers Discusses Her Cancer Diagnosis And Thinking Of Her ‘Mortality’ Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t...
